RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc. is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal healing and function. The Companyís product pipeline is comprised of two ongoing clinical trials (RCT-01: tendon repair and RCS-01: skin rejuvenation) as well as its RCH-01: hair restoration product under exclusive license by Shiseido Company for certain Asian countries. All product candidates are based on RepliCelís innovative technology, utilizing cell populations isolated from a patientís healthy hair follicles. The Company has also developed a proprietary injection device (RCI-02) optimized for the administration of its products and licensable for use with other dermatology applications.

Expert Comments:

Douglas Loe, Echelon Growth Partners (3/28/17)
"We are increasing our RepliCel Life Sciences Inc. price target to $3.50 from $2.15. . .we believe our valuation is conservative when considering how solidly RepliCel has demonstrated functional improvement in at least two cell therapy markets, and with new Achilles tendon repair data serving as evidence for how NBDS could be relevant to other orthopedic/tendon repair markets like rotator cuff injury, or lateral epicondytis or patellar tendinitis, all with similar pathology to Achilles tendinosis. Our model solely values RCT-01 in Achilles tendinosis for now, since that is the only active tendon repair program in RepliCelís pipeline."

RepliCel's successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development.
read more >
Douglas Loe, Echelon Growth Partners (3/14/17)
"We are unambiguously positive about what new two-year data suggests about future clinical performance in this [androgenetic alopecia] market, and how it validates RepliCel Life Sciences Inc.ís DSC platform overall. . . RCH- 01 did hit its primary endpoint that was defined mostly by safety and adverse event rate criteria. . .we now have two-year data to show that RCH-01 had a measurable impact on hair density in a sizable proportion of patients, though we will be interested to see on longer-term follow-up."

Shane Matte, BioTuesdays Publishing Co. (3/14/17)
"RepliCel Life Sciences Inc. has successfully completed its first-in-human clinical study of the company's autologous cell therapy for the treatment of androgenetic alopecia (pattern baldness). The Phase 1 trial met its endpoints and sets the stage for next steps in ongoing research and development of its product, RCH-01, for the treatment of male and female androgenetic alopecia. . .the five-year trial data set has confirmed the complete safety profile of a high-dose of dermal sheath cup cells (DSCC) for patients with pattern baldness due to androgenetic alopecia. No serious adverse events were reported over the entire 60.5-month follow-up period of the trial."

James Brumley, SmallCap Network (2/28/17)
"RepliCel Life Sciences Inc., which is working on a trio of aesthetic treatments and one medical device, announced on Tuesday morning it had inked deals with two manufacturers to build some prototypes of the company's planned hardware. Not only is it a sign of progress, for RP investors who looked past the focal point of the press release, the company snuck in a couple of details about the three clinical trials it's also got underway. . .the company is moving more rapidly than perhaps most RP shareholders have expected."

Douglas Loe, Echelon Growth Partners (2/28/17)
"RepliCel Life Sciences Inc. announced that it has identified two new two European manufacturers with which it will collaborate going forward on development of its patented Pelletier element cooled dermal injector RCI-02. . .two new manufacturing alliances places dermal injector RCI-02 on track for EU regulatory filing and CE Mark review in 2018. . .the firm formally announced the closing of two separate financings announced in early Feb, cumulatively raising gross proceeds of $3.1M through the sale of 2.53M share-and-warrant units, for which net proceeds to RepliCel of $2.9M solidly reduce financial risk to its ongoing clinical programs."

George Mack, BioDecade (2/16/17)
"An analyst could show investors the size of these marketsóskin aging, Achilles heel and hair restorationóand any of the three could represent total markets worth billions of dollars. There is an opportunity to carve out hundreds of millions in revenue to produce an extraordinary, eye-opening top line. . .focus on RepliCel Life Sciences Inc.ís current minimalist market cap of under $US20 million and the fact that movement of these clinical studies into phase 2 and phase 3 could mean a very significant increase in share price. RepliCel represents an undiscovered opportunity, but its low market cap precludes mutual funds and pensions from owning it."

More Expert Comments

Experts Following This Company

Douglas Loe, Analyst – Euro Pacific Canada
George Mack, Interviewer – BioDecade
Shane Matte – BioTuesdays Publishing Co.
Colin Lee Novick, Managing Director – CJ PARTNERS

The information provided above is from analysts, newsletters, the company and other contributors.

RepliCel Life Sciences Inc. is a sponsor of Streetwise Reports.†The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
Data announcements from 3 different clinical trials in Q1 2017
Biotech company focused on large aesthetic and sports injury markets
Small-cap biotech company expected to be generating revenue in 2018
catalyst Calendar